Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra Birnkrant

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|December 28, 2019
Gender Parity in Clinical PrEP TrialsJeffrey Murray, Debra Birnkrant
The New England Journal of Medicine|November 4, 2009
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenzaDebra Birnkrant, Edward Cox
Hepatology (Baltimore, Md.)|May 9, 2015
Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designsPoonam Mishra, Jeffrey Murray, Debra Birnkrant
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2018
Leveraging the Success of HIV Drug Development Paradigms for CancerGideon M Blumenthal, Debra Birnkrant, Richard Pazdur
The New England Journal of Medicine|August 3, 2022
Tecovirimat and the Treatment of Monkeypox - Past, Present, and Future ConsiderationsAdam Sherwat, John T Brooks, Debra Birnkrant, et al.
The New England Journal of Medicine|October 3, 2009
CDC and FDA response to risk of confusion in dosing Tamiflu oral suspensionDaniel S Budnitz, Linda L Lewis, Nadine Shehab, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2012
Reply to Ison et AlAlfred Sorbello, S Christopher Jones, Debra Birnkrant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2012
Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisionsJiang Liu, Jeffry Florian, Debra Birnkrant, et al.
Hepatology (Baltimore, Md.)|October 24, 2017
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluationKimberly Struble, Kirk Chan-Tack, Karen Qi, et al.
Hepatology (Baltimore, Md.)|November 22, 2007
Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendationsKenneth E Sherman, Russell Fleischer, Katherine Laessig, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|December 28, 2019
Gender Parity in Clinical PrEP TrialsJeffrey Murray, Debra Birnkrant
The New England Journal of Medicine|November 4, 2009
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenzaDebra Birnkrant, Edward Cox
Hepatology (Baltimore, Md.)|May 9, 2015
Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designsPoonam Mishra, Jeffrey Murray, Debra Birnkrant
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2018
Leveraging the Success of HIV Drug Development Paradigms for CancerGideon M Blumenthal, Debra Birnkrant, Richard Pazdur
The New England Journal of Medicine|August 3, 2022
Tecovirimat and the Treatment of Monkeypox - Past, Present, and Future ConsiderationsAdam Sherwat, John T Brooks, Debra Birnkrant, et al.
The New England Journal of Medicine|October 3, 2009
CDC and FDA response to risk of confusion in dosing Tamiflu oral suspensionDaniel S Budnitz, Linda L Lewis, Nadine Shehab, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2012
Reply to Ison et AlAlfred Sorbello, S Christopher Jones, Debra Birnkrant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2012
Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisionsJiang Liu, Jeffry Florian, Debra Birnkrant, et al.
Hepatology (Baltimore, Md.)|October 24, 2017
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluationKimberly Struble, Kirk Chan-Tack, Karen Qi, et al.
Hepatology (Baltimore, Md.)|November 22, 2007
Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendationsKenneth E Sherman, Russell Fleischer, Katherine Laessig, et al.
Pageof 3